Cronos vs Natural Alternatives International
CRON and NAII side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRON and NAII compare
Cronos is the larger company, worth 59 times as much as Natural Alternatives International ($1.2B against $19.9M).
Cronos grew revenue faster over the last twelve months (37.5% versus 9.7% for Natural Alternatives International).
Cronos keeps more of each dollar of sales as profit, with a net margin of 39.1% compared with −14.5% at Natural Alternatives International.
Cronos scores higher on the StockData Score (15 against 6 for Natural Alternatives International), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRON | NAII |
|---|---|---|
| Size and price | ||
| Market cap | $1.2B | $19.9M |
| Share price | $3.19 | $0.901 |
| Change, 1 year | 30.2% | −71.6% |
| Change, 5 years | −31.7% | −93.1% |
| Beta (5Y) | 0.06 | 0.11 |
| Employees | 610 | 219 |
| StockData Score | ||
| Total score | 15 (better) | 6 |
| Valuation score | 3 (better) | 1 |
| Growth score | 3 (better) | 1 |
| Performance score | 3 (better) | 2 |
| Health score | 6 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 15.9× | – |
| P/S | 6.6× | 0.1× (better) |
| P/B | 1.1× | 0.4× (better) |
| EV/EBITDA | 75.1× | – |
| P/FCF | 23.6× | – |
| FCF yield | 4.2% (better) | −63.3% |
| Fair value | $3.56 | – |
| Margin of safety | 10.4% | – |
| Growth | ||
| Revenue growth (TTM) | 37.5% (better) | 9.7% |
| Revenue growth, 5Y average | 25.7% (better) | −4.4% |
| Net income growth (TTM) | 278% | – |
| EPS growth (TTM) | 300% | – |
| Profitability | ||
| Gross margin | 45.9% (better) | 6.3% |
| Operating margin | −1.4% (better) | −13.2% |
| Net margin | 39.1% (better) | −14.5% |
| FCF margin | 27.8% (better) | −8.9% |
| Return on equity | 6.5% (better) | −35.0% |
| Return on invested capital | −0.93% (better) | −25.2% |
| Financial health | ||
| Debt / equity | 0.00 | 0.20 (better) |
| Current ratio | 16.18 (better) | 1.73 |
| Altman Z-score | 12.90 (better) | 1.49 |
| Piotroski F-score | 7 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | 3.3% (better) | 0.45% |
| Shareholder yield | 3.3% (better) | 0.45% |
| Ownership | ||
| Held by institutions | 12.9% | 10.5% |
| Held by insiders | 7.0% | 5.0% |
| Insider net buying, 12 months | – | $26.8K |
| Short interest, % of float | 1.2% | 0.03% |
Go deeper
- CRON stock overview
- CRON income statement
- CRON valuation and score
- NAII stock overview
- NAII income statement
- NAII valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.